







































      Toxic epidermal necrolysis (TEN) is an acute life-threatening 
mucocutaneous disorder with an estimated incidence of 0.4
1.9/1,000,000 and a mortality higher than 20%40% and is 
mostly drug-related (80%95%)[1]. It is clinically characterized as 
a widespread sloughing of the skin and mucosa on both external 
and internal surfaces. Histologically, the denuded areas show full 
thickness epidermal necrosis.
      Pemetrexed is a multitargeted antifolate drug approved for use 
in metastatic nonsmall cell lung cancer (NSCLC). AP regimen 
(pemetrexed plus cisplatin) is the preferred first-line chemotherapy 
for non-squamous NSCLC. The most common adverse events 
of pemetrexed include myelosuppression and gastrointestinal 
toxicity; cutaneous toxicity usually occurs as grades 12 rash. 
There also exist some severe cases that present acute generalized 
exanthematous pustulosis (AGEP), painful generalized erythematous 
patches, urticarial vasculitis[2-4], and TEN. To our knowledge, TEN 





kinase inhibitor (TKI) extensively used as the first-line treatment 
for -mutant metastatic NSCLC. The most common adverse 
effects include acne-like rash, diarrhea, and nausea, most of which 
are mild (grade 1/2) and reversible, and predominantly begin within 
the first treatment cycle. The acne-like rash (folliculitis) has been 
described variously as acne, rash, macropapular rash, pustular 




















      A 42-year-old woman diagnosed with stage IV NSCLC 
(adenocarcinoma) was admitted to our hospital in August 2013 and 
given an AP regimen (pemetrexed 500 mg/m2 on day 1, cisplatin 
75 mg/m2 on days 1 to 3, repeated every 3 weeks) as initial 
chemotherapy on August 2nd, 2013. She received folate, vitamin 
B12, and corticosteroids as recommended. Several days later, 
her  genetic test results demonstrated an exon 19 mutation 
(L747-T751>P); thus, she started taking gefitinib (250 mg once 
daily) on August 15th. On August 23th, which was 21 days after 
AP chemotherapy and 8 days after gefitinib treatment, the patient 
suddenly developed a widespread eruption including acne-like rash 
on the face, erythema papules on the trunk and limbs, oral ulcer, and 
conjunctivitis ("#$ and 1B), followed by a fever of 39°C. The 
rash gradually increased and aggravated, accompanied with blisters, 
pruritus, and ulceration. Twelve days after gefitinib treatment, the 




as prophylaxis, and diphenhydramine and loratadine were given as 
an anti-allergy treatment. On the 13th day, the patient’s condition 
deteriorated further with a fever of 42°C, fused mucocutaneous rash 
as well as diffuse vesicles and bullae ("#: and 1D), which 
coalesced and then sloughed, presenting a scalded appearance. 
A positive Nikolsky sign was present on her back and feet ("
1E and #). After consulting dermatology doctors, the patient was 
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count of 6.26 × 109/L [reference value: (3.699.16) × 109/L], 
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L); both the Mycoplasma pneumoniae IgM antibody and Mac strains 
were negative. No suspicious fungus was found in the oral swab 
examination, nor did bacteria grow in the skin secretion culture.
      Immunosuppressive treatment was started with 100 mg 
methylprednisolone (daily injection) for 9 days and intravenous 
immunoglobulin (20 g/day) for 5 days, followed by 10 g/day for 5 
days, accompanied with imipenem and teicoplanin for anti-infection 
and other supportive treatment. This treatment led to a recurrence 
of the rash and the mucosal lesions, reepithelization of the denuded 
skin ("}), and improvement of the patient’s general condition 






treatment. The combination of AP and gefitinib was suspended; 
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TKI made in China) after recovery, without exfoliative dermatitis or 











      Most TEN cases result from hypersensitive reaction to drugs, 
and sulfonamides, pyrazolones, barbiturates, and antiepileptics are 





implicated drugs, it may develop within hours.
      TEN is a T-cell–mediated disease with CD8+ T cells acting as 
the major mediator of keratinocyte death. Drug-induced CD8+ T-cell 
activation is highly specific for particular human leukocyte antigen 
(HLA) allotypes, placing certain populations at a greater risk of 








granzyme B/perforin are important in the pathogenesis of TEN[10]. 
      The diagnosis of TEN is made based on clinical and histological 
findings. Schwartz et al .[11] put forward that the clinical features of 
TEN include (1) constitutional symptoms such as fever, malaise, 
anorexia, and pharyngitis; (2) erythematous, dusky, violaceous 
macules, morbilliform, or atypical targetoid macules starting on 
the trunk and spreading distally, confluence on the face, trunk, 
and elsewhere [the skin lesion area of TEN is greater than that of 
Stevens-Johnson syndrome (SJS)]; (3) manifests in flaccid bullae, 
epidermal sloughing, and necrosis with gray hue; (4) exfoliation of 
the epidermis involving 10% of body surface area for SJS, 10%30% 
for SJS/TEN overlap, and >30% for TEN; (5) oral, genital, and ocular 
mucositis in nearly all patients; (6) tender skin and painful mucosal 
erosions; (7) positive Nikolsky sign; (8) positive Asboe-Hansen sign; 
(9) systemic symptoms always present in SJS/TEN overlap and TEN; 
and (10) respiratory tract epithelial involvement in 25% of patients 
with TEN. Histological features were described as follows: (1) full 
thickness epidermal necrosis; (2) subepidermal split, lymphocytic 
 "&:+ T cells in the dermis, 
and CD8+ T cells in the epidermis; and (3) endothelial apoptosis[11].




includes SJS, acute generalized exanthematous pustulosis (AGEP), 
erythema multiforme major (EMM), staphylococcal scalded skin 
syndrome (SSSS), drug-induced linear immunoglobulin A (IgA) 
dermatosis, acute graft versus host disease (GVHD), and a 
generalized morbilliform drug eruption, among other conditions[12,13]. 
Our patient’s clinical characteristics were consistent with the above 
criteria except items (8) and (10). Because the patient’s exfoliation 
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excluded due to negative blood and rash cultures for bacteria and 
fungus as well as the presence of conjunctiva and oral mucosa 
damage. In addition, the patient’s rash mainly appeared as blisters 
and bullae due to erythema in the beginning stage, without pustules. 
Accordingly, AGEP and other diseases were also excluded.
      Therefore, the patient was diagnosed with TEN according to 
typical clinical features. After treatment with glucocorticoids combined 
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the diagnosis of TEN. However, there also exists some deficiency 
in the diagnosis of this case, primarily the lack of mucocutaneous 
biopsy and immunologic examination to aid in the diagnosis.
      There is currently no standardized treatment for TEN. An effec-
tive treatment requires early diagnosis, immediate discontinuation 






the major therapeutic regimen, and glucocorticoids combined 
with immunoglobulin can quickly control symptoms and shorten 
hospitalization time and is especially suitable for patients with 
concurrent infection[11].
      Because this case of TEN occurred after AP and gefitinib 
sequential combination treatment, it is difficult to determine which 
drug was responsible for this toxicity. Thus far, there has been 
no report of TEN induced by cisplatin, whereas there has only 
been one case of SJS related to bleomycin-cisplatin combination 
treatment[14] and another case of exfoliative dermatitis associated 
with cyclophosphamide-cisplatin combination treatment[15]. To the 
best of our knowledge, 4 cases of TEN due to pemetrexed have been 
reported thus far: 1 due to pemetrexed alone, 1 related to pemetrexed 







cycle and 15 days after the second cycle of drug administration. 
Pemetrexed seems to be the most likely cause for our TEN case. 
Although our patient received gefitinib after AP chemotherapy, 





which supports pemetrexed as the initiator.
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 @induced TEN thus 
far, gefitinib could not be ruled out for the cause of this case as 
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and attachment, and cutaneous toxicity occurs in more than 50% 
of patients. Meanwhile, TEN occurring after 8 days of gefitinib 
administration has also increased the suspicion of gefitinib as the 






TEN induced by pemetrexed. Meanwhile, is there any possibility for 
@induced mucocutaneous disorder 
based on the alternation of folic acid metabolism of epithelial cells by 
pemetrexed? It is still unknown. 
      In summary, we report this case with the intent to further 
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